Insmed files U.S. marketing application for inhaled amikacin for type of lung disease; shares up 2% [Seeking Alpha]
Insmed Incorporated (INSM)
Last insmed incorporated earnings: 4/30 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.insmed.com
Company Research
Source: Seeking Alpha
Insmed files U.S. marketing application for inhaled amikacin for type of lung disease; shares up 2%Insmed (INSM+1.6%)submits a New Drug Application (NDA) to the FDA seeking approval for ALIS (amikacin liposome inhalation suspension) for the treatment of adult patients with nontuberculous mycobacterial lung disease caused byMycobacterium avium complex. There are currently no approved therapies in the U.S. for the condition.The company says it expects a six-month review period considering ALIS's Orphan Drug, Breakthrough Therapy and Qualified Infectious Disease Product (QIDP) status.Previously:Insmed's inhalable amikacin successful in late-stage study, shares up 77% premarket (Sept. 5, 2017)See all stocks on the move »Now read:The Time To Buy Things Is When They're On Sale! »
Show less
Read more
Impact Snapshot
Event Time:
INSM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
INSM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
INSM alerts
High impacting Insmed Incorporated news events
Weekly update
A roundup of the hottest topics
INSM
News
- Insmed Incorporated (NASDAQ: INSM) is now covered by analysts at Truist Financial Co.. They set a "buy" rating and a $48.00 price target on the stock.MarketBeat
- Insmed Incorporated (NASDAQ: INSM) had its price target raised by analysts at Barclays PLC from $37.00 to $40.00. They now have an "overweight" rating on the stock.MarketBeat
- What Makes Insmed (INSM) a Lucrative Investment? [Yahoo! Finance]Yahoo! Finance
- Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)PR Newswire
- Insmed Incorporated (NASDAQ: INSM) had its "overweight" rating re-affirmed by analysts at Wells Fargo & Company. They now have a $55.00 price target on the stock.MarketBeat
INSM
Earnings
- 2/22/24 - Miss
INSM
Sec Filings
- 4/1/24 - Form DEFA14A
- 4/1/24 - Form DEF
- 3/11/24 - Form 8-K
- INSM's page on the SEC website